CYTK Relative Valuation
CYTK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CYTK is overvalued; if below, it's undervalued.
Historical Valuation
Cytokinetics Inc (CYTK) is now in the Undervalued zone, suggesting that its current forward PS ratio of 99.16 is considered Undervalued compared with the five-year average of -9.68. The fair price of Cytokinetics Inc (CYTK) is between 264.66 to 328.69 according to relative valuation methord. Compared to the current price of 64.53 USD , Cytokinetics Inc is Undervalued By 75.62%.
Relative Value
Fair Zone
264.66-328.69
Current Price：64.53
75.62%
Undervalued
-10.11
PE
1Y
3Y
5Y
-11.16
EV/EBITDA
Cytokinetics Inc. (CYTK) has a current EV/EBITDA of -11.16. The 5-year average EV/EBITDA is -9.74. The thresholds are as follows: Strongly Undervalued below -15.01, Undervalued between -15.01 and -12.37, Fairly Valued between -7.11 and -12.37, Overvalued between -7.11 and -4.48, and Strongly Overvalued above -4.48. The current Forward EV/EBITDA of -11.16 falls within the Historic Trend Line -Fairly Valued range.
-11.16
EV/EBIT
Cytokinetics Inc. (CYTK) has a current EV/EBIT of -11.16. The 5-year average EV/EBIT is -9.84. The thresholds are as follows: Strongly Undervalued below -14.95, Undervalued between -14.95 and -12.39, Fairly Valued between -7.28 and -12.39, Overvalued between -7.28 and -4.72, and Strongly Overvalued above -4.72. The current Forward EV/EBIT of -11.16 falls within the Historic Trend Line -Fairly Valued range.
99.16
PS
Cytokinetics Inc. (CYTK) has a current PS of 99.16. The 5-year average PS is 182.94. The thresholds are as follows: Strongly Undervalued below -210.70, Undervalued between -210.70 and -13.88, Fairly Valued between 379.76 and -13.88, Overvalued between 379.76 and 576.58, and Strongly Overvalued above 576.58. The current Forward PS of 99.16 falls within the Historic Trend Line -Fairly Valued range.
-12.01
P/OCF
Cytokinetics Inc. (CYTK) has a current P/OCF of -12.01. The 5-year average P/OCF is -10.81. The thresholds are as follows: Strongly Undervalued below -18.66, Undervalued between -18.66 and -14.74, Fairly Valued between -6.88 and -14.74, Overvalued between -6.88 and -2.95, and Strongly Overvalued above -2.95. The current Forward P/OCF of -12.01 falls within the Historic Trend Line -Fairly Valued range.
-13.36
P/FCF
Cytokinetics Inc. (CYTK) has a current P/FCF of -13.36. The 5-year average P/FCF is -11.33. The thresholds are as follows: Strongly Undervalued below -19.96, Undervalued between -19.96 and -15.65, Fairly Valued between -7.02 and -15.65, Overvalued between -7.02 and -2.71, and Strongly Overvalued above -2.71. The current Forward P/FCF of -13.36 falls within the Historic Trend Line -Fairly Valued range.
Cytokinetics Inc (CYTK) has a current Price-to-Book (P/B) ratio of -14.48. Compared to its 3-year average P/B ratio of -49.31 , the current P/B ratio is approximately -70.63% higher. Relative to its 5-year average P/B ratio of -29.37, the current P/B ratio is about -50.68% higher. Cytokinetics Inc (CYTK) has a Forward Free Cash Flow (FCF) yield of approximately -6.01%. Compared to its 3-year average FCF yield of -8.62%, the current FCF yield is approximately -30.30% lower. Relative to its 5-year average FCF yield of -6.58% , the current FCF yield is about -8.65% lower.
-14.48
P/B
Median3y
-49.31
Median5y
-29.37
-6.01
FCF Yield
Median3y
-8.62
Median5y
-6.58
Competitors Valuation Multiple
The average P/S ratio for CYTK's competitors is 1581.42, providing a benchmark for relative valuation. Cytokinetics Inc Corp (CYTK) exhibits a P/S ratio of 99.16, which is -93.73% above the industry average. Given its robust revenue growth of 318.14%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CYTK increased by 30.61% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 463.00K to 1.94M.
The secondary factor is the Margin Expansion, contributed -54.39%to the performance.
Overall, the performance of CYTK in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
MAIN
Main Street Capital Corp
61.06USD
-2.01%
NE
Noble Corporation PLC
28.9675USD
-2.99%
NUVL
Nuvalent Inc
101.86USD
4.79%
WFRD
Weatherford International PLC
87.26USD
-2.37%
TKR
Timken Co
88.45USD
-2.75%
CRUS
Cirrus Logic Inc
117.35USD
-4.64%
INSP
Inspire Medical Systems Inc
97.85USD
0.66%
NOVT
Novanta Inc
124.73USD
0.03%
VLY
Valley National Bancorp
12.075USD
-0.04%
HXL
Hexcel Corp
79.06USD
0.83%
Frequently Asked Questions
Is Cytokinetics Inc (CYTK) currently overvalued or undervalued?
Cytokinetics Inc (CYTK) is now in the Undervalued zone, suggesting that its current forward PS ratio of 99.16 is considered Undervalued compared with the five-year average of -9.68. The fair price of Cytokinetics Inc (CYTK) is between 264.66 to 328.69 according to relative valuation methord. Compared to the current price of 64.53 USD , Cytokinetics Inc is Undervalued By 75.62% .
What is Cytokinetics Inc (CYTK) fair value?
CYTK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Cytokinetics Inc (CYTK) is between 264.66 to 328.69 according to relative valuation methord.
How does CYTK's valuation metrics compare to the industry average?
The average P/S ratio for CYTK's competitors is 1581.42, providing a benchmark for relative valuation. Cytokinetics Inc Corp (CYTK) exhibits a P/S ratio of 99.16, which is -93.73% above the industry average. Given its robust revenue growth of 318.14%, this premium appears sustainable.
What is the current P/B ratio for Cytokinetics Inc (CYTK) as of Jan 07 2026?
As of Jan 07 2026, Cytokinetics Inc (CYTK) has a P/B ratio of -14.48. This indicates that the market values CYTK at -14.48 times its book value.
What is the current FCF Yield for Cytokinetics Inc (CYTK) as of Jan 07 2026?
As of Jan 07 2026, Cytokinetics Inc (CYTK) has a FCF Yield of -6.01%. This means that for every dollar of Cytokinetics Inc’s market capitalization, the company generates -6.01 cents in free cash flow.
What is the current Forward P/E ratio for Cytokinetics Inc (CYTK) as of Jan 07 2026?
As of Jan 07 2026, Cytokinetics Inc (CYTK) has a Forward P/E ratio of -10.11. This means the market is willing to pay $-10.11 for every dollar of Cytokinetics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Cytokinetics Inc (CYTK) as of Jan 07 2026?
As of Jan 07 2026, Cytokinetics Inc (CYTK) has a Forward P/S ratio of 99.16. This means the market is valuing CYTK at $99.16 for every dollar of expected revenue over the next 12 months.